Key Drivers of Coagulation Factor Use in Von Willebrand Disease During Hospitalization: An Overview of the French BERHLINGO Cohort-Reference-Cited by-同舟云学术

Key Drivers of Coagulation Factor Use in Von Willebrand Disease During Hospitalization: An Overview of the French BERHLINGO Cohort

Published:2023-11-30 Issue:1 Volume:44 Page:35-49
ISSN:1173-2563
Container-title:Clinical Drug Investigation
language:en
Short-container-title:Clin Drug Investig

Author:

Horvais Valérie^ORCID,Beurrier Philippe,Cussac Vincent^ORCID,Pan-Petesch Brigitte^ORCID,Schirr-Bonnans Solène^ORCID,Rose Johann^ORCID,Bayart Sophie,Ternisien Catherine,Fouassier Marc^ORCID,Sigaud Marianne^ORCID,Babuty Antoine^ORCID,Drillaud Nicolas^ORCID,Guillet Benoît^ORCID,Trossaërt Marc^ORCID,Cochennec Sabrina,Cornec Magalie,Drugmanne Guillaume,Galinat Hubert,Gouin Isabelle,Leroy Estelle,Nedelec-Gac Fabienne,

Funder

Baxalta GmbH, a wholly subsidiary of Takeda Pharmaceutical Company Limited

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s40261-023-01323-1.pdf

Reference37 articles.

1. Sharma R, Flood VH. Advances in the diagnosis and treatment of Von Willebrand disease. Blood. 2017;130:2386–91. https://doi.org/10.1182/blood-2017-05-782029.

2. Fressinaud É. Clinical, biological and molecular diagnosis. Hématologie. 2014;30–49. DOI: https://doi.org/10.1684/hma.2014.0885

3. Goodeve A, James P. von Willebrand disease. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJ, Stephens K, et al. editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993 [cited 2018 May 17]. http://www.ncbi.nlm.nih.gov/books/NBK7014/. Bookshelf ID: NBK7014.

4. Swami A, Kaur V. von Willebrand disease: a concise review and update for the practicing physician. Clin Appl Thromb Hemost. 2017;23:900–10. https://doi.org/10.1177/1076029616675969.

5. Boisseau P. Molecular genetic techniques. Hématologie. 2014. https://doi.org/10.1684/hma.2014.0884.